Global Hemophilia A and B Industry Drug Forecast

307 views

Published on

The Report “PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with “PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022″ in subject line and your contact details to purchase this report or get your questions answered.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Argentina ranks fourth among pharmaceutical markets in Latin America. According to primary research, the majority of Argentine hemophilia patients have access to recombinant FVIII and RIX products through private insurance plans or through the national social security program. However, the national insurance program only covers on-demand treatment and plasma-derived concentrates.
Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=141247 .
Scope
• Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Argentina including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Argentina from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market.
Complete report is available @ http://www.rnrmarketresearch.com/pharmapoint-hemophilia-a-and-b-argentina-drug-forecast-and-market-analysis-to-2022-market-report.html . Read more on “PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022” report below.

Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012-2022 in Argentina
Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=141247 .

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
307
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Hemophilia A and B Industry Drug Forecast

  1. 1. PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022 by GlobalData Explore all reports for “ Hematology Therapeutics ” market @ http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/therapeutics/hematologytherapeutics . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  2. 2. PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022 The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Argentina ranks fourth among pharmaceutical markets in Latin America. According to primary research, the majority of Argentine hemophilia patients have access to recombinant FVIII and RIX products through private insurance plans or through the national social security program. However, the national insurance program only covers on-demand treatment and plasma-derived concentrates. Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=141247 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  3. 3. PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022 Scope •Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. •Detailed information on the key drugs in Argentina including product description, safety and efficacy profiles as well as a SWOT analysis. •Sales forecast for the top drugs in Argentina from 2012-2022. •Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market. Complete Report Available @ http://www.rnrmarketresearch.com/pharmapoint-hemophilia-a-and-b-argentinadrug-forecast-and-market-analysis-to-2022-market-report.html . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  4. 4. PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022 Reasons to buy •Understand and capitalize by identifying products that are most likely to ensure a robust return •Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B •Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential •Make more informed business decisions from insightful and in-depth analysis of drug performance •Obtain sales forecast for drugs from 2012-2022 in Argentina Buy a copy of report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=141247 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  5. 5. PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022 Table of Contents 1 Table of Contents 4 1.1 List of Tables 7 1.2 List of Figures 9 2 Introduction 10 2.1 Catalyst 10 2.2 Related Reports 11 2.3 Upcoming Related Reports 13 3 Disease Overview 14 3.1 Etiology and Pathophysiology 14 3.1.1 Etiology 14 3.1.2 Pathophysiology 15 Request Sample copy of this report @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=141247 . © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441
  6. 6. PharmaPoint: Hemophilia A and B – Argentina Drug Forecast and Market Analysis to 2022 For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441 RnR Market Research RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe. © RnRMarketResearch.com ; sales@rnrmarketresearch.com ; +1 888 391 5441

×